ACT Capital Partners, L.P.’s Nektar Therapeutics NKTR Stock Holding History

ACT Capital Partners, L.P.’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$5.47M	Buy	+90,400	New	+$6.35M	3.56%	10

Other funds holding NKTR

Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Iridian Asset Management Westport, Connecticut $275M AUM 37.66% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

APEIRON Capital Ltd Hong Kong $73.7M AUM 81.83% 1-Year Est. Return

Moody Aldrich Partners Marblehead, Massachusetts $523M AUM 75.24% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

ACT Capital Partners, L.P.'s NKTR Position: Q3 2026 in Review

ACT Capital Partners, L.P. opened a new position in Nektar Therapeutics (NKTR) in Q3 2026: 90,400 shares worth $5.47M. The stake represents 3.56% of the portfolio and ranks #10 among its holdings.

65 funds tracked by Wall St. Rank hold NKTR as of Q3 2026.

ACT Capital Partners, L.P. held 90,400 shares of Nektar Therapeutics worth $5.47M as of Q3 2026.
Nektar Therapeutics was a new ACT Capital Partners, L.P. position in Q3 2026.
Nektar Therapeutics made up 3.56% of ACT Capital Partners, L.P.'s portfolio in Q3 2026, its #10 holding.
65 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2026.

Based on ACT Capital Partners, L.P.'s 13F filing for Q3 2026, filed 6 Nov 2026.